NCT Number: NCT02199873
Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of BIIX 1 XX, to determine the pharmacologically active dose (range) by performing a methacholine challenge test and to obtain preliminary pharmacokinetic data
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–50 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy male volunteers who have Broca-Indices within +-20%
- Participants in the age range between 21 to 50 years
- Following the methacholine challenge the airway resistance (Raw) shows an increase of at least 130%
- In accordance with Good Clinical Practice (GCP) and local legislation each volunteer is supposed to give his written informed consent prior to admission to the study
- As part of the screening (within 14 days before drug administration), each subject was to receive a complete medical examination (including blood pressure, pulse rate, medical history, documentation of demographics, inclusion/exclusion criteria and concomitant therapy) as well as a 12-lead Electrocardiogram (ECG)
- Haematopoietic, hepatic and renal function test will be carried out in the laboratory
- The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first administration of the test substance
Exclusion criteria
- Volunteers will be excluded from the study if the results of the medical examination or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
- Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Volunteers with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
- History of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of a drug with a long half-life (>= 24 hours) within one month before enrolment in the study
- Use of any drugs which might influence the results of the trial the week previous to the start of the study
- Participation in another study with an investigational drug within the last two months preceding this study
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- Inability to refrain from smoking on study days
- Alcohol abuse (> 60g/day)
- Drug abuse
- Blood donation within the last 4 weeks
- Excessive physical activities within the last week before the study
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Number of subjects with adverse events
Time frame: up to 3 months
-
Number of subjects with abnormal changes in laboratory parameters
Time frame: up to 8 days after last drug administration
-
Change in impedance cardiography
Time frame: up to 30 minutes after drug administration
-
Change in cutaneous microcirculation
Time frame: up to 30 minutes after drug administration
Secondary outcomes
-
Change in airway resistance (Raw) after methacholine challenge
Time frame: up to 30 minutes after drug administration
-
Change in specific conductance (sGaw) after methacholine challenge
Time frame: up to 30 minutes after drug administration
-
AUC (Area under the concentration-time curve of the analyte in plasma)
Time frame: up to 168 hours after drug administration
-
Cmax (Maximum measured concentration of the analyte in plasma)
Time frame: up to 168 hours after drug administration
-
tmax (Time from dosing to the maximum concentration of the analyte in plasma)
Time frame: up to 168 hours after drug administration
-
Ae (Amount of analyte that is eliminated in urine)
Time frame: up to 48 hours after drug administration
-
MRT (Mean residence time of the analyte in the body)
Time frame: up to 168 hours after drug administration
-
t½ (Terminal half-life of the analyte in plasma)
Time frame: up to 168 hours after drug administration
-
CL/F(Apparent clearance of the analyte in plasma following extravascular administration)
Time frame: up to 168 hours after drug administration
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Methacholine Challenge) Study After Inhalational Administration of BIIX 1 XX (Single Doses: 5 - 800 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)
Important dates
- Study start
- 1998
- Primary completion
- 1998
- First posted
- Jul 25, 2014
- Registry last updated
- Oct 29, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details